Objective: Medically unexplained somatic complaints are highly prevalent, and lead to significant impairment and disability. The number of effective treatment modalities for somatic symptom and related disorders (SSDs) or somatoform disorders (SDs) remains limited. To date, there is no formal indication for electroconvulsive therapy (ECT) in SSD or SD. We report on the largest case series to date regarding the effectiveness of ECT in patients with SSD and SD. Methods: A retrospective chart review of all patients treated with an index course of ECT at the Neuropsychiatric Program at the University of British Columbia Hospital from 2000 to 2010 was conducted. The primary outcomes consisted of changes in pseudoneurologic symptoms, pain symptoms, cardiopulmonary symptoms, and gastrointestinal symptoms. Complaints were examined pre-and post-ECT. Results: Twenty-eight participants were included in this study. Twenty-one participants received right unilateral ECT. Six received bifrontal ECT. One received bitemporal ECT. Eighteen of 21 participants reported improvement in pseudoneurologic symptoms; eleven of 14 participants reported improvement in pain symptoms; one participant reported improvement in cardiopulmonary symptoms; and one of two participants reported improvement in gastrointestinal symptoms. This paper discusses the putative mechanism of action of ECT in the treatment of SD/SSD. Conclusion: This retrospective study suggests that ECT could be included as part of the existing treatment for refractory SSD and SD, particularly in refractory cases with comorbid mood disorders.
Background
Somatic symptom and related disorder (SSD), as defined in DSM-5, is characterized by somatic symptoms that are either very distressing or result in significant disruption of functioning. They could lead to excessive and disproportionate thoughts, feelings, and behaviors in relation to those symptoms. To be diagnosed with SSD, the individual must be persistently symptomatic. Two important clinical implications of the changes from DSM-IV-TR to DSM-5 are 1) hypochondriasis and body dysmorphic disorder are no longer considered as part of the SSD and 2) medically unexplained symptomatology is no longer required to make a diagnosis of SSD. This second aspect reflects a change in the conceptualization of SSD, that the interplay between medical conditions and psychiatric symptoms is a continuum with coexistence of medical and psychiatric features rather than a mind-body dichotomy. 1 Since DSM-5 was only recently introduced, most published reports have utilized the older DSM-IV-TR framework. Epidemiological studies on somatoform disorders (SDs) have shown that the prevalence of medically unexplained somatic complaints in primary care settings is very high. 2, 3 These symptoms cause significant impairment and disability, and management of these patients represents an enormous cost to the health care system. [4] [5] [6] Furthermore, SDs are often comorbid with psychiatric disorders such as depression and anxiety. 7, 8 Specifically, a previous epidemiological study in the general population demonstrated that up to 22% of the patients with somatization disorder or pain disorder (PD) had at least one comorbid psychiatric diagnosis including mood disorders. 9 Finally, studies in the primary care settings have shown a "dose-response" relationship between the number of physical symptoms and prevalence of mood and anxiety disorders. Comorbid anxiety or mood disorders occur in 44%-60% of patients who suffered from six or more physical symptoms independent of geographical or economic factors. 10, 11 With regard to management, SSDs are amenable to numerous strategies including cognitive behavioral therapy and pharmacotherapy. 1, 12, 13 Prognosis tends to be more favorable when a model of stepped and shared care is used. 14 However, in the most severe, treatment-refractory cases, even when multidisciplinary care is combined with complex augmentation and pharmacological therapies, prognosis often remains guarded. 15 In severe treatment-refractory SD, the use of electroconvulsive therapy (ECT) is increasingly being recognized as an effective treatment modality. ECT is a noninvasive convulsive neurostimulation treatment. With modified ECT, a brief, controlled generalized seizure is elicited by means of an electrical current applied to the patient's scalp while under general anesthesia. A wealth of evidence supports the use of ECT in many psychiatric conditions such as major depressive disorder (MDD), bipolar disorder, schizoaffective disorder, and schizophrenia. 16 In fact, it is the most effective treatment for depression, with close to 80% response and remission rates. 16 In treatment-refractory depression, the response rates following ECT are close to 60% and were found to be significantly higher than pharmacotherapy. 17 Moreover, there are clinical situations where ECT is considered first-line treatment (eg, severe catatonic state, severe acute suicidality). 18 However, the use of ECT is often limited by temporary cognitive side effects such as anterograde and short-term retrograde amnesia.
The overlap in etiopathogenesis combined with the epidemiological evidence showing a high degree of comorbidity between SDD and MDD have led clinicians to consider the use of ECT in SSD, and particularly in its most severe and refractory presentations. Indeed, there are case reports on the use of ECT with good outcomes in conversion disorder (CD), [19] [20] [21] [22] in somatization disorder and SD not otherwise specified, 23, 24 and in PD. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Even though these case reports suggest positive outcomes using ECT for SSD, it is important to highlight several limitations including low number of cases and patient heterogeneity.
In the current study, we attempted to examine the extent to which ECT was effective in the treatment of SSD using a large case series of patients with SD treated with ECT. In addition, we examined the extent to which patients with the following groups of symptoms responded to an index regimen of ECT: pseudoneurological symptoms, pain symptoms, cardiopulmonary symptoms, and gastrointestinal (GI) symptoms. We hypothesized that ECT would be effective in these groups of symptoms, as suggested by previous case reports on SD.
Patients and methods
A retrospective chart review of all patients treated with an index course of ECT, at the BC Neuropsychiatry Program at the University of British Columbia Hospital from 2000 to 2010 was performed. This tertiary subspecialty program has an outpatient department and a ten-bed inpatient unit for the assessment and treatment of complex neuropsychiatric cases including medically unexplained conditions in the province of British Columbia, Canada.
For this study, all patients admitted to the neuropsychiatry inpatient ward receiving ECT from 2000 to 2010 were reviewed. Cases were selected based on the clear DSM-IV-TR diagnosis of SD as the main reason for admission and treatment and where ECT was specifically initiated with SD being the primary target of treatment.
Baseline information was collected and included the following: demographics (age, sex), DSM-IV-TR diagnoses, age of onset of the SD, duration of illness, number of medication trials before starting ECT, ECT parameters (placement of electrodes, stimulus parameters, anesthetic agent used for ECT), and outcome of ECT course (clinical change and adverse effects). Electrode placement (ie, right unilateral [RUL], bifrontal [BF], or bitemporal [BT]) was noted including the starting placement and any subsequent adjustments. During the decade from 2000 to 2010, all patients at the UBC Hospital were treated with the Thymatron System IV ECT machine by Somatics, Inc., set at 0.5 ms (brief) stimulus pulse width. Seizure duration was monitored using the electroencephalogram strip of bilateral frontopolar electrical activity.
In this study, the main outcome measure consisted of the participants' subjective change in clinical symptoms throughout the course of ECT (ie, pseudoneurologic, pain, 
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ecT for somatoform disorders cardiopulmonary, and GI symptoms). Each subject was assessed clinically by his/her assigned psychiatrist at least thrice weekly. These physiological systems were chosen to reflect commonly associated complaints in SSD and SD, independent of the changes from the DSM-IV-TR to DSM-5 criteria. When available, the depression outcome measures, such as Beck Depression Inventory (BDI) and Geriatric Depression Scale (GDS), were used to capture the change in depressive symptoms pre-and post-ECT treatment.
Ethical approval was obtained from the University of British Columbia Human Research Ethics Board and from the Vancouver Costal Health Research Institute. Patient consent was not required as no personal identifiers are mentioned.
Results

Demographics and clinical characteristics
In this case series, 28 participants (16 females and 12 males) who suffered from SD were treated with an index course of ECT (Table 1) . Mean age of all participants was 48.7 years, and standard deviation (StDev) was 12 years.
The mean length of unemployment secondary to SD was 6.05 years (StDev 4.77 years) based on data from 25 patients, and detailed data were unavailable for three patients. The unemployment rate prior to ECT treatment was 100%. The mean, StDev, and range for the number of nonpsychiatric specialists consulted for their physical complaint(s) seen prior to ECT were 6.2, 3.3, and 0-13, respectively.
Among all participants, using the coded DSM-IV-TR diagnosis recorded in the charts at the time of admission, 14 participants suffered from CD, three suffered from PD, nine had comorbid pain and CD, and two had SD not otherwise specified. The mean duration, StDev, and range of length of illness prior to ECT were 9 years, 7 years, and 1-28 years, respectively. The mean number of psychiatric comorbidities (SD) was 2.5 (1.2). The mean, StDev, and range for the number of medical comorbidities were 4.39, 3.33, and 0-11, respectively. The mean number of antidepressant trials prior to starting ECT was 2.89 (StDev 0.89), and the mean number of antipsychotics trials prior to starting ECT was 2.1 (StDev 0.99). Due to the physical complaints, the average number of medications other than psychotropics (antidepressant, mood stabilizers, benzodiazepine, and antipsychotics) being taken was 2.29 (StDev 1.8).
ecT parameters and results
Twenty-one participants began the study with RUL electrode placement (Tables 2 and 3 ). Among the participants beginning with unilateral placement, 14 of 21 participants (67%) were subsequently switched to bilateral placement due to 
cardiopulmonary symptoms
One participant reported significant shortness of breath in addition to extremity pain and urinary incontinence. He was 62 years old and had the above-mentioned symptoms for close to 10 years. In terms of psychiatric comorbidities, he had comorbid MDD, anxiety, and psychotic symptoms. In terms of medical history, he had no cardiovascular risk factors but had a history of pulmonary sarcoidosis (in remission a Two participants had not responded initially to subsequent ecT trials but improved after more courses of ecT. symptoms from one of these two participants went in remission with more courses of ecT. Abbreviation: ecT, electroconvulsive therapy. 
clinical outcomes
Eighteen of 21 patients (86%) with pseudoneurologic symptoms reported subjective significant improvement. Two patients in this group reported no significant changes and one patient reported subjective deterioration of her symptoms following ECT.
Eleven of 14 patients (79%) with pain symptoms reported significant subjective improvement by the end of the index course. Three patients (21%) in this group reported subjective worsening of their pain following ECT.
The only patient with cardiopulmonary symptoms reported moderate improvements in his mood, pain, and cardiopulmonary symptoms.
Of two patients with GI symptoms, one patient discontinued ECT prematurely due to lack of clinical efficacy and one patient reported significant improvement in GI symptoms.
In terms of mood symptoms, many of our participants reported subjective improvement. In three participants, subjects 2, 3, and 5, we captured changes in mood symptoms using the self-reported GDS, which revealed −6, −12, and +2, respectively, pre-and post-ECT treatment. In the other three participants, subjects 8, 18, and 20, we captured changes in mood symptoms using the BDI, which revealed −14, −20, and −5 points, respectively.
In total, 22 of 28 patients were assessed to have shown significant improvement with regard to their SD/SSD-related physical symptoms after an index course of ECT. Table 5 summarized the characteristics of the six nonresponders to ECT treatment for their somatic symptoms.
Discussion
At this time, we believe this is the largest case series published on SSD/SD treated with ECT. In this case series, we used a symptoms-based approach to examine the extent to which an index course of ECT led to clinical changes across four categories of symptoms: pseudoneurologic complaints, pain, cardiopulmonary, and GI symptoms. Several key observations can be made.
First, from the review of demographic information, the inability to work due to disability was high in the population of SD patients reported in this study. This speaks of the severity and functional disruption posed by this condition. Second, SD were not mutually exclusive. In fact, the clinical symptoms of 13 participants in this study would qualify for more than one SD using the DSM-IV-TR criteria used at the time when these patients were treated. Third, SD were highly comorbid with mood and anxiety disorders. In fact, all participants (100%) had comorbid MDD. PTSD was comorbid in ten of the 28 (36%) participants in this case series. Finally, 22 of 28 (79%) patients in this case series reported significant Note that all subjects identified in this table had a comorbid MDD. Abbreviations: BF, bifrontal placement; cD, conversion disorder; ecT, electroconvulsive therapy; F, female; gi, gastrointestinal symptoms; M, male; Pain, pain disorder; Pseud-Neu, pseudoneurological symptoms; RUL, right unilateral placement; Som-NOS, somatoform disorder not otherwise specified; MDD, major depressive disorder; Dx, diagnosis; rx, prescription. Evidence suggests that SSD and SD are psychiatric disorders that could be caused by functional abnormalities of the central nervous system rather than being only "diseases of the mind". 41 Studies have supported probable neurobiological underpinnings of somatoform symptoms. 8, [42] [43] [44] [45] [46] [47] Recently, Dukart et al 48 reported the potential for ECT to create long-term structural changes in the limbic system and in the prefrontal cortex. Similarly, several studies have shown that ECT may affect regional cerebral blood flows or cerebral metabolic rates. [49] [50] [51] Whether the reported improvements in somatoform symptoms in the current study could be correlated with neurobiological changes post-ECT will require further investigations.
Although the precise mechanism of action of ECT remains unclear, converging lines of evidence point to the interaction between the neuroendocrine and immunologic systems modulated by ECT as a current hypothesis. Both MDD and SD/SSD have been suggested to share similar abnormalities in the neuroendocrine and immunologic systems. 52 In patients with MDD, ECT has been shown to increase the level of brain-derived neurotrophic factor, often found to be at a decreased level in depression and tends to normalize when treated with antidepressant medications. 53, 54 In addition, electrically induced seizures in animal models have demonstrated an increase in neurogenesis and synaptic plasticity in the hippocampus 55, 56 and in the rostral-medial striatum. 57 It is possible that these observed neurobiological changes could lead to improvement in monoamine neurotransmitters functioning. 58 Ernst et al 59 in a recent article, discussed the possibility that neurogenesis in the adult human brain could extend beyond the hippocampi to the striatum. As an important player of the limbic system, the striatum could play a significant role in emotion regulation in a multitude of psychiatric disorders. 60 Hence, ECT could lead to improvement in psychiatric symptoms through optimization of neurogenesis and synaptic plasticity. Moreover, ECT was found to play a significant role in the modulation of the immunological system, including psychiatric illness. 61, 62 It is believed that the protracted effects of stressors and cytokines may play an important role in the pathophysiology of amplification of somatic complaints. 63 Early evidence suggested that ECT could bring about a balance between inhibition and activation of the immunological system. For example, ECT was found to attenuate the proinflammatory state by inducing long-lasting changes in macrophage function in mice 64 and to increase lymphocytic expression of activation antigens and natural killer cell activity. 62 Furthermore, ECT has been shown to decrease the levels of tumor necrosis factor in severe depressive disorder, hence decreasing the level of proinflammatory molecules present in severe MDD. 65 Finally, ECT appears to decrease the levels of tumor necrosis factor in severe MDD, again decreasing the level of the proinflammatory state. 65 In this report, the observed changes in SSD and SD symptoms post-ECT might be primarily related to the effect of adequate treatment of psychiatric comorbidities such as MDD. In fact, one of ECT's main indications is MDD. 66 Hurwitz 67 described that the pathophysiology of conversion symptoms may begin with a psychiatric illness, most commonly depression, and that somatoform symptoms serve as "a somatic defense to govern behavior", thereby leading to nonorganic findings on clinical examination. Of note, somatic delusions are often encountered in severe MDD. 68 In this report, whether MDD preceded or followed the onset of important somatic symptoms remained unknown. As described earlier, substantial epidemiological studies have shown high rates of comorbidity between SSD and mood disorders. In this series, despite inconsistent objective measures used for the assessment of pre-and post-ECT levels of depression, a number of our participants showed improvement in the GDS and BDI.
When drawing conclusions from this case series, one should be mindful that this is a retrospective collection of case reports, with all the implied limitations. In addition, with the recent changes in the SSD DSM-5 diagnostic criteria, we decided to focus on describing the effects of ECT on various somatic systems rather than focus on the disorders as described in the DSM. Therefore, we cannot know if ECT would be beneficial for all disorders in this classification even though on the whole, the majority of patients appeared to have benefited from the treatment. In this report, medication adjustments and psychotherapeutic interventions were not controlled for during the ECT treatment, thus raising the possibility that symptomatic improvements may have been related to factors other than ECT. Furthermore, it is important to highlight that outcome measures were subjective and potentially open to bias. Yet, we share the results of the response to ECT of this group of individuals suffering severe, chronic, treatment-refractory somatic symptoms with comorbid depression in the belief that clinicians in the field attempting to help patients in similar situations may benefit from knowing that many such patients appeared to improve clinically with this modality of treatment. A prospective design with rigorous diagnostic consistency, controlling for medication and psychotherapeutic changes, and objective outcome measures would be needed to overcome these limitations. 
Conclusion
Although we cannot advise that ECT should be used broadly for the treatment of SSD based on this report, we believe this case series adds further support to the existing literature on the effectiveness of ECT. Based on the cases presented, the majority of patients with chronic refractory SSD with comorbid MDD benefited from the ECT treatment. We noted the improvement in both somatic features and affective symptoms.
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